Your browser version may not work well with NCBI's Web applications. More information here...
1: Pain. 1996 Oct;67(2-3):375-8.Links

Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks.

May A, Gijsman HJ, Wallnöfer A, Jones R, Diener HC, Ferrari MD.

Department of Neurology, University of Essen, Germany.

Bosentan, a specific mixed antagonist of endothelin receptors with no vasoconstrictor activity, inhibits neurogenic plasma extravasation (NPE) within rat dura mater. This would predict efficacy in aborting migraine attacks, without causing cardiovascular side-effects. We investigated the efficacy of 250 mg i.v. bosentan in a randomized, double-blind, placebo-controlled, clinical trial. Improvement from moderate/severe to mild/no headache at 2 h (primary efficacy measure) occurred in 5/23 (22%) of bosentan-treated and in 9/25 (36%) of placebo-treated patients (effect difference -14%; 95% CI -52%, 24%). Thus, inhibition of NPE may not predict clinical efficacy of experimental antimigraine drugs. Vasoconstrictor action may be needed.

PMID: 8951932 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Bosentan (Tracleer® )

    Bosentan is used to treat pulmonary arterial hypertension (PAH, high blood pressure in the vessels that carry blood to the lungs). Bosentan may improve the ability to exercise and slow the worsening of symptoms in patien...

  • Source: AHFS Consumer Medication Information